Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial outlook for fiscal year 2015 following the FDA response letter on the Company’s lead product Epi proColon®. As communicated in the past, such a decision has a significant impact on the achievement of certain projected financial parameters for 2015.
The Company’s financial outlook for 2015 changes as follows:
Revenue is projected to exceed last year’s figure of EUR 1.5 million, which is significantly less than the projected EUR 3-4 million. In the first nine months 2015, Epigenomics recorded revenue of EUR 1.3 million* (9M 2014: EUR 1.1 million).
EBIT is now projected at the lower end, or may slightly fall short, of the previous outlook range of EUR -10.0 to -11.0 million. Cash consumption is projected at the upper end of, or may slightly exceed, the previous outlook range of EUR 9.5 to 10.5 million.
*preliminary; final report on first nine months of 2015 will be published on November 18, 2015
– End of Ad hoc –
Contact Epigenomics AG
Peter Vogt, Investor & Public Relations
Phone +49 (0) 30 24345 386
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.